How many drugs treat Essential hypertension?

Drug Landscape tracks 3 marketed treatments for Essential hypertension (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/essential-hypertension.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Essential hypertension — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Essential hypertension (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Essential hypertension, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cetapril	ALACEPRIL	Par Pharm	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1981-01-01
Verapamil Hydrochloride	Verapamil Hydrochloride	Pfizer Inc.	Calcium channel blocker	L-type calcium channels (slow channels)
Moxonidin	Moxonidin	University of Aarhus		5-hydroxytryptamine receptor 1A, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Essential hypertension
Par Pharm · 1 drug in Essential hypertension
Pfizer Inc. · 1 drug in Essential hypertension
University of Aarhus · 1 drug in Essential hypertension

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Essential hypertension:

Cite this brief

Drug Landscape (2026). Essential hypertension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/essential-hypertension. Accessed 2026-06-10.

Essential hypertension full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing